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Abstract
Background: Intracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer’s disease
(AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space
such as cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Although clearance is one critical parameter leading to
such intracellular/extracellular tau accumulation, in vivo turnover of tau has not been well characterized. The current
study has attempted to precisely determine in vivo turnover rates of tau utilizing tet-off regulatable mice. In particular,
we assessed intracellular tau and extracellular tau, soluble tau, insoluble tau and phosphorylated tau at certain sites
utilizing a combination of in vivo microdialysis, biochemical analysis and specific ELISAs recognizing each species. To
examine the effect of a tauopathy-associated mutation on tau clearance, half-lives of various tau species were
compared between the mice with a FTDP-17 mutation that induces β-sheet formation, ΔK280 mutation (pro-aggregant
mice) and control mice with additional β-sheet breaking mutations (anti-aggregant mice).
Results: Here we report that tau is metabolized at much slower turnover rates in vivo than in cell culture.
We found that insoluble tau in pro-aggregant mice had a significantly slower half-life (t1/2 = ~34.2 days) than
soluble tau (t1/2 = ~9.7 days). In contrast, soluble tau phosphorylated in the proline rich region was cleared
faster than total soluble tau. When comparing pro-aggregant mice to anti-agregant mice, turnover rates of
soluble tau species were not significantly different.
Conclusions: The current study provides a comprehensive description of in vivo turnover of various tau species
present in mice that express human tau. The turnover rate of soluble tau was not significantly altered between
pro-aggregant mice and anti-aggregant mice. This suggests that altered conformation by ΔK280 does not have a
major impact on clearance pathways for soluble tau. In contrast, different tau species displayed different half-lives.
Turnover was significantly delayed for insoluble tau whereas it was accelerated for soluble tau phosphorylated in
the proline rich region. These differences in susceptibilities to clearance suggest that aggregation and phosphorylation
influences tau clearance which may be important in tau pathogenesis.
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Background
Abnormal tau aggregates as NFTs are common patho-
logical hallmarks in a set of neurodegenerative diseases
called tauopathies including AD, progressive supra-
nuclear palsy, corticobasal degeneration, and certain
forms of frontotemporal lobar dementia. Tau is physio-
logically highly soluble, however under pathological
conditions, it changes its conformation to one with a
high β–sheet content, undergoes hyperphosphorylation
and forms aggregates including filaments and NFTs in
the cytoplasm.
NFTs are formed intracellularly, however, extracellular
tau also has pathological significance. For example, tau
in CSF is elevated in individuals with AD and preclinical
AD. In addition, recent studies have demonstrated that
tau pathology may be transmitted from neuron to
neuron via the extracellular space [1–5].
Growing evidence suggests that tau contributes to neur-
onal dysfunction. Chronic inhibition of tau expression in
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various mouse models protects them against cognitive
impairments [6–8]. This leads to the idea that lowering
tau production may be a potential therapeutic strategy.
Since clearance pathways mediate tau protein levels,
the development of tau-lowering therapy would benefit
from a better understanding of in vivo turnover of tau.
While a number of studies have focused on how tau is
metabolized in cultured cells [9–14], surprisingly little
is known about in vivo clearance of tau, especially
pathologically relevant tau species that accumulate in
the tauopathies such as aggregated forms of tau, extra-
cellular tau, and phosphorylated tau. Therefore, an ana-
lysis of the in vivo turnover rate of tau in mice that
develop tauopathy will not only deepen our under-
standing of tau clearance at the systemic level but also
assist in interpreting tau changes in the clinical setting.
In order to directly address this issue, we set out to
evaluate in vivo turnover rates of tau in animal models
that accumulate pathogenic tau species. In this study, we
utilized tet-off tau transgenic mice called pro-aggregant
mice, which express a regulatable human 2N4R tau cDNA
with a ΔK280 tau mutation. These mice develop age-
dependent tau aggregation [6, 15, 16]. We examined
turnover rates of intracellular soluble tau, insoluble
tau, phosphorylated tau and extracellular soluble tau
by coupling biochemical analysis and in vivo microdi-
alysis with specific ELISAs recognizing different tau
species. Here we report that in vivo turnover rates of
tau were significantly longer than in cell culture. Suscepti-
bility to clearance varies among different tau species.
Intracellular insoluble tau displayed a significantly lon-
ger half-life in pro-aggregant mice and soluble tau
phosphorylated in the proline rich region showed faster
turnover rates than total soluble tau. When turnover
rates of soluble tau were compared between pro-
aggregant mice and aged matched control mice with a
β-sheet breaking mutation in tau called anti-aggregant
mice [17], significant differences were not observed.
Results and discussion
Strategy to investigate turnover of intracellular soluble
tau, insoluble tau, phosphorylated tau and extracellular
tau in tet-off regulatable tau transgenic mice
To examine turnover rates of various tau species
in vivo, we utilized tet-off tau transgenic mice, called
pro-aggregant mice [6, 15, 16]. Pro-aggregant mice
express a 2N4R isoform of human tau with a ΔK280
mutation, which is found in a family with FTDP-17
[18] (Fig. 1a). This mutation modifies MAPT splicing
leading to an increase of three repeat isoform, how-
ever four repeat isoform with this ΔK280 mutation
is still produced [18, 19], which enhances propensity
of tau to form β-sheet structure. In these mice, tau
changes its conformation to a form containing high
β-sheet content, forms insoluble aggregates and undergoes
hyperphosphorylation, which allows us to assess vari-
ous pathologically relevant tau species. Although the
16–17 month old mice that we utilized in this study
had not yet developed pronounced NFTs at this
age, they have detergent insoluble tau [16] and display
synapse loss and cognitive decline, which can be
reversed when tau expression is suppressed [6].
The expression of human tau in these mice can be
specifically switched off by doxycycline. Therefore
the rate at which tau steady-state levels decline fol-
lowing doxycycline treatment will reflect its half-life.
In addition, the expression of human tau is kept
intentionally low to avoid disturbance of endogenous
metabolism in these mice.
The outline of our experimental design is illustrated in
Fig. 1. Tau is present not only in the intracellular com-
partment but also in the extracellular space. To distin-
guish clearance of extracellular tau from intracellular
tau, microdialysis was performed in the hippocampus
during doxycycline treatment prior to brain collection
(Fig. 1b, c). Since the microdialysis technique works on
the principle of the diffusion of molecules in solution
across a semi-permeable membrane, microdialysis sam-
ples contain extracellular soluble tau in ISF which is less
than 1,000 kDa, the molecular weight cut-off of the
probes [20].
To examine intracellular tau, hippocampal homoge-
nates were prepared at the end of doxycycline treatment
(Fig. 1b, c). Brain samples include both intracellular and
extracellular proteins. However tau is predominantly
present intracellularly [21], thus tau in hippocampal ho-
mogenates represents mostly intracellular tau (Fig. 1c).
The hippocampus was immediately dissected after mi-
crodialysis experiments and biochemically processed by
serial extraction using reassembly buffer (RAB), RIPA,
70 % formic acid to obtain soluble and insoluble intra-
cellular fractions (Fig. 1b, c). Tau levels were quantified
in these fractions (We defined each fraction as follows;
ISF = extracellular soluble fraction, hippocampus sol-
uble fraction = intracellular soluble fraction, hippocam-
pus insoluble fraction = intracellular insoluble fraction)
by ELISA (Fig. 1c). We utilized a combination of Tau5
and biotinylated HT7 (HT7B) antibodies to detect hu-
man tau and HJ9.2 and biotinylated HJ8.7 (HJ8.7B)
antibodies to detect murine tau respectively. We first
checked the specificity of these ELISAs using brain ho-
mogenates from hTau mice, which express human tau
on a murine tau knockout background along with wild-
type and tau knockout mice as controls [22]. Tau5/
HT7B ELISA detected tau only in brain homogenates
of hTau mice (Fig. 1d). In contrast, the HJ9.2/HJ8.7B
ELISA only detected tau in wildtype mice (Fig. 1e). This
demonstates that our assays are highly specific to
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human or murine tau. After tau levels were mea-
sured by ELISA, log-transformed tau levels were
plotted over days treated with doxycycline along with
a linear regression curve and turnover rates were de-
termined by analyzing the slope as previously de-
scribed [20, 23] (Fig. 1f ).
Turnover of soluble tau in pro-aggregant mice and anti-
aggregant mice
By using hippocampal soluble fractions, we first in-
vestigated turnover rates of intracellular soluble tau
in 16–17 month old pro-aggregant mice. In these
fractions, doxycycline specifically reduced human but
not murine tau as expected (Fig. 2a). A linear regression
of semi-log plot (Fig. 2c) revealed that the estimated
half-life of intracellular soluble tau in pro-aggregant
mice was 9.7 days (Table 1). The half-life of tau deter-
mined in cell culture ranges from ~5 to 60 h [9–12, 24].
The significantly longer half-life of tau indicates that tau
metabolism is different between cells and the in vivo
environment.
To examine clearance of extracellular tau, in vivo
microdialysis was performed in the pro-aggregant
mice. Doxycycline treated resulted in a trend of re-
duction in human tau with no change in ISF lactate
(Fig. 2b). The half-life of extracellular tau in pro-
Fig. 1 Schematic illustration of regulatable tau transgenic mice and experimental design. a Illustration of tau transgene in pro-aggregant mice
and anti-aggregant mice. b A schematic representation of in vivo microdialysis during doxycycline treatment. Human tau expression was
suppressed by doxycycline in 16–17 month old pro-aggregant mice or anti-aggregant mice for a period indicated in the white box. ISF
was collected for 2 days indicated in the gray box while doxycyline administration continued. The mean levels of ISF human tau were
plotted against time indicated in arrows. Immediately after microdialysis experiments, the hippocampus was dissected (day of hippocampus collection).
c Experimental scheme for collection of extracellular and intracellular tau in this study. Microdialysis probes with 1,000 kDa cut-off membranes were
inserted in hippocampus to collect soluble extracellular tau in ISF. To measure intracellular tau, the hippocampus was homogenized in 3-step
serial extraction with RAB, RIPA and 70 % Formic acid (FA) (See the details in methods section). d Tau5/HT7B ELISA specifically detects human
tau. Tau levels in RAB fractions from Tau knockout mice (Tau KO) or wildtype mice or hTau mice were analyzed by Tau5/HT7B ELISA (n = 4/group,
****p < 0.0001). e HJ9.2/HJ8.7B ELISA specifically detects murine tau. Tau levels in RAB lysates from Tau knockout mice (Tau KO) or wildtype mice or
hTau mice were analyzed by HJ9.2/HJ8.7B ELISA (n = 4/group, ****p < 0.0001). f Schematic diagram for calculation of half-life. Log-transformed values
are fit with a linear regression and slope k’ was obtained from linear regression to calculate t1/2. Differences in slopes reflect alteration in clearance
(white circles for faster clearance, black circles for slower clearance)
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aggregant mice was 17.3 days (Table 1). Although a
trend was seen suggesting that extracellular soluble
tau has a longer half-life than intracellular soluble tau
(Table 1, intracellular soluble vs. extracellular soluble,
p = 0.06), turnover rates were not significantly differ-
ent (Fig. 2c).
Prior studies have linked dysfunction in protein me-
tabolism with disease-associated mutations. For ex-
ample, TDP-43 mutations linked to amyotrophic lateral
sclerosis exhibit a longer half-life [25]. Alpha-synuclein
with an A53T mutation associated with familial Parkinson’s
disease also has increased stability [26]. It is unknown
whether tau mutations could also have a similar effect
on metabolism. In order to ask whether a longer half-
life of tau in pro-aggregant mice is due to the
conformational change driven by the ΔK280 mutation,
turnover of tau in pro-aggregant mice was compared
with 16–17 month old anti-aggregant mice where tau
cannot form a β-sheet structure due to additional
double proline mutations. There was no significant
difference in half-lives of both intracellular soluble tau
and extracellular soluble tau between pro-aggregant
mice and anti-aggregant mice (Table 2). This suggests
that altered conformation by the ΔK280 mutation does not
have a profound effect on clearance of soluble tau. Import-
antly, in vivo half-lives of intracellular soluble tau de-
termined for pro-aggregant mice and anti-aggregant
mice are comparable to the half-life of endogenous
murine tau in brain estimated by stable-isotope label-
ing [27]. This supports the idea that longer half-life
Fig. 2 Turnover of soluble tau in pro-aggregant mice and anti-aggregant mice. a Doxycycline specifically reduced human tau in intracellular
fractions of pro-aggregant mice. Human (black bars) and murine tau levels (white bars) in intracellular soluble fractions following doxycycline
treatment were measured (n = 4 for day 10, n = 5 for day 4 and day 18, n = 7 for day 8, n = 12 for day 0. ****p < 0.0001) in pro-aggregant mice.
b Doxycycline specifically reduced human tau in ISF of pro-aggregant mice. The levels of human tau (black bars) and lactate (white bars) in
ISF of pro-aggregant following doxycycline treatment were measured (n = 6 for day 0, n = 5 for day 3, n = 4 for day 7, n = 4 for day 9, n = 5 for day 17,
n = 4-6/group). c Semi-log plot of intracellular (black circles) and extracellular soluble human tau (white circles) changes (Log % soluble human tau)
over time in pro-aggregant mice d Phosphorylated tau showed different clearance kinetics in brain of pro-aggregant mice. Semi-log plot of soluble
human tau (white circles, Log % soluble human tau), and phosphorylated soluble tau (black circles, Log % soluble human pS202/pT205, gray squares,
Log % soluble pT231/pS235 tau, white squares, Log % soluble murine and human pS202/pT205, white triangles, Log % soluble human pS396) over
time in pro-aggregant mice. e Phosphorylated tau showed different clearance kinetics in the brain of anti-aggregant mice. Semi-log plot of soluble
human tau (white circles, Log % soluble human tau), and phosphorylated soluble tau (black circles, Log % soluble human pS202/pT205, gray triangles,
Log % phosphorylated murine and human tau pS202/pT205, white squares, Log % soluble human pS396) over time in anti-aggregant mice
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of tau in tet-off tau transgenic mice is unlikely to de-
rive from technical differences or over-expression.
Aberrant phosphorylation of tau is one of the key fea-
tures of AD. To see whether phosphorylation alters
turnover of soluble tau, we investigated the half-life of
human phosphorylated tau at S202/T205 and T231/
S235 by using human tau specific HJ8.5 antibody [28]
along with phospho-specific antibodies AT8 and AT180
antibodies in ELISAs. We found that intracellular sol-
uble tau phosphorylated at S202/T205 and T231/S235
displayed faster turnover rates than total soluble tau in
pro-aggregant mice (Fig. 2d). The half-life of tau phos-
phorylated at S202/T205 and T231/S235 was 5.7 days
and 5.2 days respectively (Table 1). The turnover rate of
phosphorylated human tau at S202/T205 was also
faster in anti-aggregant mice and it was similar to
that seen in pro-aggregant mice (Fig. 2e, Tables 1
and 2). In order to examine whether this faster
turnover is indeed due to faster clearance, we utilized
an ELISA that equally detects both murine and hu-
man phosphorylated tau using the HJ8.7 antibody
(which recognizes both murine and human tau) in-
stead of the human tau specific HJ8.5 antibody. We
did not observe faster decline of phosphorylated tau
in both pro-aggregant mice and anti-aggregant mice
using this assay, suggesting that faster turnover of
phosphorylated human tau is likely due to faster
clearance not due to faster turnover of the phosphate
group itself (Fig. 2e). Both S202/T205 and T231/S235
are located in the proline rich region of tau. In order
to examine the effect of phosphorylation in the carboxyl
terminal region of tau, we also investigated half-life of
human tau phosphorylated at S396. The half-life of
tau phosphorylated at S396 in pro-aggregant mice
and anti-aggregant mice was 9.8 days and 7.6 days re-
spectively (Fig. 2d, e) which is not as short as the
half-life of human tau phosphorylated at the S202/
T205 and T231/S235 sites. Taken together, this data
suggests that phosphorylation of tau at some sites differ-
entially alters susceptibility of soluble tau to clearance. In
Table 1 Half-lives of various tau species in pro-aggregant mice
and anti-aggregant mice
Pro-aggregant mice
half-life (t1/2, day) R
2
Intracellular soluble 9.7 0.91
Extracellular soluble 17.3 0.7
P 0.06
intracellular soluble 9.7 0.91
intracellular soluble pS202/pT205 5.7 0.8
P 0.12
intracellular soluble 9.7 0.91
intracellular soluble pT231/pS235 5.2 0.88
P <0.0001
intracellular soluble 9.7 0.91
intracellular insoluble 34.2 0.43
P <0.0001
intracellular soluble 9.7 0.91
intracellular soluble pS396 9.8 0.51
P 0.52
Anti-aggregant mice
half-life (t1/2, day) R
2
Intracellular soluble 11.1 0.96
Extracellular soluble 10.9 0.91
P 0.44
half-life (t1/2, day) R
2
intracellular soluble 11.1 0.96
intracellular soluble pS202/pT205 7.5 0.89
P 0.022
half-life (t1/2, day) R
2
intracellular soluble 11.1 0.96
intracellular soluble pS396 7.6 0.64
P 0.24
Table 2 The comparison of half-life of tau between pro-
aggregant mice and anti-aggregant mice
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fact, it is consistent with the studies showing that some
species of phosphorylated tau is preferentially degraded in
certain contexts [11, 13].
Turnover of intracellular insoluble tau in pro-aggregant
mice
The comparison between pro-aggregant mice and anti-
aggregant mice revealed that the turnover rate of sol-
uble tau was not different between these mice. Thus we
asked whether turnover of tau is altered when it forms
insoluble aggregates. Doxycycline resulted in a decrease
in human tau in the detergent insoluble fractions with-
out changing murine endogenous tau in pro-aggregant
mice although the decrease was not quite statistically
significant (Fig. 3a). The estimated turnover rate of in-
soluble tau was 34.2 days, suggesting that insoluble tau
is cleared significantly more slowly than soluble tau
(Fig. 3b and Table 1). Tau in insoluble fractions likely
represents tau oligomers, fibrils, and other β-sheet
enriched assemblies not present in anti-aggregant mice.
Thus the data indicates although soluble tau is nor-
mally metabolized in pro-aggregant mice, once it forms
insoluble structures, it acquires relative resistance to
degradation and clearance. Interestingly though, even
some clearance of insoluble material occurs suggesting
that endogenous mechanisms for aggregate clearance
are present.
Conclusions
In this study, we examined turnover rates of various
tau species. We found that in vivo half-life of tau is
significantly longer than tau half-life previously re-
ported in vitro studies. Therefore, reducing tau production
therapeutically will take an appreciable period of time
to reduce tau protein levels, especially pre-existing tau
aggregates than previously predicted from cell culture
studies.
We also asked whether the ΔK280 mutation influ-
ences turnover of tau. The half-life of soluble tau was
not significantly altered when comparing pro-aggregant
to anti-aggregant mice. The data suggests that despite
the propensity to altered conformation, the ΔK280 mu-
tation does not lead to a profound effect on clearance
of soluble tau. Further studies will be needed to exam-
ine whether other tau mutations have an effect on sol-
uble tau clearance.
The mechanistic reason to explain differences in the
half-life of various tau species is not known. Furthers
studies to understand the mechanisms causing differ-
ences in in vivo clearance of tau will be helpful. In
addition, the systems that clear extracellular tau in
the ISF or CSF will be particularly important to ex-
plore since they differ completely from the intracellu-
lar degradation pathways important for intracellular
tau degradation such as the proteasomal or autophagy
systems. Although it was not statistically significant
with the number of mice we had, there was a trend
that extracellular soluble tau has a longer half-life
than intracellular soluble tau in pro-aggregant mice
(t1/2 = 9.7 day for intracellular soluble tau, t1/2 = 17.3 day
for extracellular soluble tau, p = 0.06, Table 1). This
trend was not observed in anti-aggregant mice (t1/2 =
11.1 day for intracellular soluble tau, t1/2 = 10.9 day for
extracellular soluble tau, p = 0.44, Table 1) [20]. Al-
though the increasing trend in half-life of extracellular
tau in pro-aggregant mice should be further examined
Fig. 3 Turnover of intracellular insoluble tau in pro-aggregant mice. a Doxycycline specifically reduced human tau in FA fractions of pro-aggregant
mice. Human (black bars) and murine tau levels (white bars) in detergent insoluble fractions of pro-aggregant mice following doxycycline treatment
were measured. (n = 4 for day 10, n = 5 forday 4 and day 18, n = 7 for day 8, n = 12 for day 0.). b Insoluble tau showed slower turnover than soluble
tau in brain. Semi-log plot of soluble (black circles) and detergent insoluble human (white triangles) tau (Log % human tau) over time
in pro-aggregant
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with a larger number of mice, one possibility for this
trend might be that turnover of extracellular tau is
differentially influenced by the presence of tau aggre-
gates, due to an equilibrium between ISF tau and tau
aggregates. Such an equilibrium was suggested by our
group previously using P301S human tau transgenic
mice [21].
Although we are not currently able to detect soluble
tau oligomers or aggregates in the ISF by microdialysis,
it will be important to understand clearance mecha-
nisms of such extracellular tau species that facilitate the
spreading of tau pathology from cell to cell in the brain
if present. Besides its role as a diagnostic biomarker in
AD, soluble tau in CSF is being evaluated as an end-
point to validate the disease-modifying effects in vari-
ous clinical trials for AD. In addition to tau released
from dying or degenerating neurons, the long half-life
of extracellular tau actively released from neurons may
provide some important new insights to consider as to
what might be leading to elevated extracellular tau as




All animal experiments were performed and approved in
accordance with guidelines established by the Animal
Studies Committee at Washington University. Regulata-
ble transgenic mice expressing human full-length tau
cDNA (Tau 2N4R) with mutations ΔK280/PP (I277P,
I308P) (anti-aggregant mice) and mice expressing hu-
man full-length tau cDNA (Tau 2N4R) with a ΔK280
mutation (pro-aggregant mice) on C57BL/6 J back-
ground of both sexes were utilized. The mice were
screened ahead of experiments by quantifying transgene
expression via the co-expressed luciferase detected by
bioluminescence imaging [6, 15]. P301S transgenic
mice (line PS19) which overexpress P301S human T34
isoform tau (1N4R) on a B6C3 background were used
to make brain homogenates as a standard for phos-
phorylated tau measurements [29]. Three month old
tau knockout mice were obtained from the Jackson la-
boratory [30]. Five to nine month old wildtype litter-
mates of P301S transgenic mice were used as wildtype
controls. 11.5–12.5 month old hTau mice which express
wildtype human tau on a tau knockout background
were also used [22].
in vivo microdialysis
in vivo microdialysis with a 1,000 kDa molecular weight
cut-off probe to assess ISF tau levels from awake and
freely moving mice was performed as previously de-
scribed [20].
Briefly, a guide cannula (Eicom microdialysis) was
stereotactically implanted in the left hippocampus under
isoflurane anesthesia, and cemented. After implantation
of the cannula and dummy probes (Eicom microdialysis),
mice were habituated to microdialysis cages for one
more day. After this recovery period, a 2-mm 1,000-kD
cut-off AtmosLM microdialysis probe (Eicom) was
inserted through the guide cannula. As a perfusion buf-
fer, 25 % human albumin solution (Gemini Bio Inc.) was
diluted to 4 % with artificial CSF (aCSF; 1.3 mM CaCl2,
1.2 mM MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM
NaHCO3, and 122 mM NaCl, pH 7.35) on the day of
use and filtered through a 0.1 μm membrane. A
probe was connected to a microdialysis peristaltic
pump with two channels (MAB20; SciPro), which was
operated in a push-pull mode. Before microdialysis
sample collection, a pump was run at the maximum
flow rate for at least 1 h and then the flow rate was
switched to 0.5 μl/min. To avoid tissue damage, the
experimental window was set from 6 to 48 h after
probe implantation. ISF samples were collected in a
refrigerated fraction collector (SciPro) and analyzed
by ELISA.
Switch off experiments
Sixteen to seventeen month old pro-aggregant or anti-
aggregant mice were randomly divided into 5 groups.
One cohort of mice was not exposed to doxycycline-
containing food pellets (200 mg/kg, Bio-serv) and ISF
was collected for 2 days (0 day). Other cohorts of mice
received doxycycline-containing food pellets for 4, 8,
10, or 18 days respectively prior to microdialysis. On
the 2nd, 6th, 8th, or 16th day, in vivo microdialysis was
performed and ISF was collected for additional 2 days.
During microdialysis, mice were given doxycycline-
containing food pellets. Mean levels of ISF human tau,
lactate were plotted from the 3rd, 7th, 9th, or 17th day.
On the 4th, 8th, 10th, or 18th day, immediately after
the end of microdialysis experiments, brains were col-
lected. Values of % human tau in brain or ISF and %
lactate in ISF were normalized by the mean concentra-
tion present in the day 0 groups.
Brain extraction
Mice were transcardially perfused with heparin-PBS
and brains dissected and kept at −80 °C until analyzed.
Hippocampus was weighed and homogenized in well-
defined 3-step serial extraction protocol described
previously [16, 21, 28, 29]. Hippocampus was first ho-
mogenized with RAB buffer containing (100 mM
MES, 1 mM EDTA, 0.5 mM MgSO4, 750 mM NaCl,
20 mM NaF, 1 mM Na3VO4, supplemented by prote-
ase inhibitors (Complete, Roche) and phosphatase in-
hibitors (PhosSTOP, Roche). After centrifugation at
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50,000 × g for 20 min, the RAB insoluble pellet was
solubilized with RIPA buffer (150 mM NaCl, 50 mM
Tris, 0.5 % deoxycholic acid, 1 % Triton X-100, 0.5 %
SDS, 25 mM EDTA, pH 8.0, supplemented by protease in-
hibitor (Complete, Roche) and phosphatase inhibitor
(PhosSTOP, Roche)). The RIPA insoluble pellet after cen-
trifugation at 50,000 × g for 20 min was solubilized
with 70 % formic acid [21]. Tau levels in these frac-
tions were measured by various tau ELISAs described
below. Human tau was detectable in both RAB and
RIPA fractions, thus total tau levels in both fractions
were used to calculate the half-life of “intracellular
soluble tau”. Tau in 70 % formic acid fractions was
defined as the “intracellular insoluble tau”. We ob-
served high background values when we measured
phosphorylated tau in RIPA fractions with our assays,
thus only RAB fractions were used as soluble frac-
tions to reliably measure soluble phosphorylated tau
levels. To confirm the specificity of ELISAs used in
this study, hippocampus from tau knockout mice,
wildtype mice and hTau mice were homogenized with
RAB buffer and analyzed.
Tau ELISAs
Absolute levels of human and murine tau in ISF and
brains were measured by ELISAs which use a com-
bination of Tau5/biotinylated HT7 (HT7B) and HJ9.2/
biotinylated HJ8.7 (HJ8.7B) monoclonal anti-tau anti-
bodies respectively as previously described [20]. Rela-
tive levels of human tau phosphorylated at S202/T205
and T231/S235 were detected by in house ELISAs with
a combination of HJ8.5 [28]/biotinylated AT8 (Pierce)
and HJ8.5/biotinylated AT180 (Pierce) respectively. To
measure total (both murine and human) phosphory-
lated tau at S202/T205, combinations of HJ8.7/bio-
tinylated AT8 were used. HJ8.5 recognizes human tau
specifically whereas HJ8.7 has an identical affinity to-
ward murine and human tau. Human phosphorylated
tau at S396 was measured by Tau [pS396] Human
ELISA kit (Life technologies). For phosphorylated tau
measurement using in house phosphorylated tau
ELISAs, RAB soluble fractions from a 7 month old P301S
human tau transgenic mouse was used as a standard.
Thus, instead of absolute levels, relative levels of phos-
phorylated tau normalized to “0 day group” were used for
half-life calculation.
Lactate measurements in ISF
ISF lactate levels were determined with a YSI2700 bio-
chemistry analyzer (YSI Life Sciences), which quantifies
their levels with immobilized enzyme biosensors spe-
cific for the substrates [20].
The calculation of half-life
The half-life of tau was calculated as we previously re-
ported using the slope of linear regression that includes
all data points (t1/2 = 0.693/k, where k = 2.303 k’)
(Fig. 1c) [20, 23]. In order to consider the time re-
quired for transgene switch off in our strategy, we
measured luciferase activity [6]. Following doxycyc-
line treatment, bioluminescence signal intensity by
luciferase was constant for 4 h and then started to
decline (unpublished observation of KH and EMM).
This 4 h-delay time consists of less than 5.3 % of the
half-life of any form of tau assessed in this study,
suggesting that the contribution of this delay to half-
life calculation is negligible.
Statistical analysis
Data in figures represent mean ± s.e.m. The comparison
of multiple groups was done by one-way ANOVA with
Tukey’s post hoc test. Correlation coefficients (R2) were
calculated to see the goodness of fit for the linear regres-
sion. To examine statistically significant differences in
turnover rates, the slope of linear regression that in-
cludes all data points over time were compared using
analysis of covariance (ANCOVA) [31].
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